Felix Datlinger, ARVO 2021: Indocyanine Green Angiography-guided Laser Therapy of Teleangiectatic Capillaries
It was a pleasure to catch up with Felix Datlinger (Medical University of Vienna, Vienna, Austria) about his study on functional and morphological long-term outcomes of indocyanine green angiography-guided laser therapy of teleangiectatic capillaries.
- What was previously known about the functional and morphological long-term outcomes of indocyanine green angiography-guided laser therapy of teleangiectatic capillaries? (00:25)
- What were the aims and design of the study you are presenting at ARVO? (02:01)
- What were the findings of this study and what is their significance for clinical practice? (03:47)
Speaker Disclosure: Felix Datlinger has no financial or non-financial relationships or activities to declare in relation to this interview.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Lisa Glass.
Filmed in coverage of ARVO 2021.
Share this Video
Related Videos In Diabetic Macular Oedema
Jennifer Lim, ARVO 2023: Faricimab vs aflibercept in patients with DME
Faricimab inhibits both angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF)-A pathways which may extend treatment durability beyond current anti-VEGF therapies for diabetic macular edema (DME). It was a pleasure to speak with Dr Jennifer Lim (University of Illinois Chicago, IL, USA) around the treat-and-extend regimen with faricimab in the YOSEMITE/RHINE (NCT03622580/NCT03622593) trials and the […]
Jennifer Lim, ARVO 2023: Current therapeutic options for diabetic macular edema
Diabetic macular edema is characterised by exudative fluid accumulation in the macula and is the most common form of sight-threatening retinopathy in people with diabetes affecting one in 15 people with diabetes. Intraocular pharmacotherapy with anti-VEGF agents is the standard of care. It was a pleasure to speak with Dr Jennifer Lim (University of Illinois […]
Andreas Pollreisz, ARVO 2023: Phase 3 YOSEMITE/RHINE trial: faricimab versus aflibercept in patients with DME
The YOSEMITE/RHINE (NCT03622580/NCT03622593) trials were double-masked, active comparator–controlled, phase 3 trials investigating the efficacy, safety, and durability of faricimab 6.0 mg versus aflibercept 2.0 mg in patients with diabetic macular edema (DME). It was a pleasure to speak with Dr Andreas Pollreisz (Medical University of Vienna, Austria) around the YOSEMITE/RHINE trials as well as their […]
Journal articles and more to your inbox
Get the latest clinical insights from touchOPHTHALMOLOGYSign me up!